Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Moderate

sildenafil tovorafenib

Applies to: Revatio (sildenafil), tovorafenib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with tovorafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4. The proposed mechanism is increased clearance due to tovorafenib-mediated induction of CYP450 3A4 metabolism. According to the manufacturer, tovorafenib is predicted to decrease the peak plasma concentration (Cmax) and systemic exposure (AUC) of sensitive 3A4 substrate midazolam by at least 20%. However, data from formal clinical drug interaction studies are not available.

MANAGEMENT: Caution is recommended with the concomitant use of tovorafenib and CYP450 3A4 substrates. In particular, the manufacturer of tovorafenib advises that concomitant use with sensitive CYP450 3A4 substrates with narrow therapeutic ranges should generally be avoided. If coadministration is required, patients should be monitored carefully for potential loss of therapeutic effects.

Drug and food interactions

Moderate

sildenafil food

Applies to: Revatio (sildenafil)

If you are receiving therapy with sildenafil you should avoid the regular consumption of large amounts of grapefruits and grapefruit juice. Grapefruit can raise the levels of sildenafil in your body and delay the time it takes for the medication to work. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.